Eli Lilly and Co (LLY) : Bellecapital International Ltd. added new position in Eli Lilly and Co during the most recent quarter end. The investment management firm now holds 2,800 shares of Eli Lilly and Co which is valued at $224,616 , the company said in a statement filed on Aug 11, 2016 with the SEC.Eli Lilly and Co makes up approximately 0.23% of Bellecapital International Ltd.’s portfolio.
Other Hedge Funds, Including , Johnson Investment Counsel Inc reduced its stake in LLY by selling 324 shares or 1.05% in the most recent quarter. The Hedge Fund company now holds 30,654 shares of LLY which is valued at $2,459,064. Eli Lilly and Co makes up approx 0.08% of Johnson Investment Counsel Inc’s portfolio.River Wealth Advisors boosted its stake in LLY in the latest quarter, The investment management firm added 4 additional shares and now holds a total of 4,056 shares of Eli Lilly and Co which is valued at $330,807. Eli Lilly and Co makes up approx 0.18% of River Wealth Advisors’s portfolio.First Niagara Bank boosted its stake in LLY in the latest quarter, The investment management firm added 3,000 additional shares and now holds a total of 10,737 shares of Eli Lilly and Co which is valued at $895,466. Eli Lilly and Co makes up approx 0.25% of First Niagara Bank’s portfolio.Rockland Trust Co boosted its stake in LLY in the latest quarter, The investment management firm added 1,715 additional shares and now holds a total of 31,715 shares of Eli Lilly and Co which is valued at $2,587,627. Eli Lilly and Co makes up approx 0.43% of Rockland Trust Co’s portfolio. Boys Arnold Co Inc added LLY to its portfolio by purchasing 19,429 company shares during the most recent quarter which is valued at $1,553,349. Eli Lilly and Co makes up approx 0.26% of Boys Arnold Co Inc’s portfolio.
Eli Lilly and Co opened for trading at $79.68 and hit $79.97 on the upside on Tuesday, eventually ending the session at $79.57, with a gain of 0.35% or 0.28 points. The heightened volatility saw the trading volume jump to 34,07,537 shares. Company has a market cap of $87,833 M.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.